Nova Patents
AT536374T

Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals

Abstract

The present invention describes transgenic animals having a human (or humanized) immunoglobulin locus and a transgene encoding a human (or humanized) Ig [alpha] and / or Ig [beta] sequence. And / or the endogenous Ig [alpha] and / or Ig [beta] sequences of an animal having a transgene heavy and light chain immunoglobulin locus capable of producing a diverse human (or humanized) antibody profile, Production is inhibited. (Or humanized) Ig [alpha] and / or Ig [beta] such that normal B cell development, human (or humanized) antibody affinity maturation, and high-level expression are expressed concurrently with human (or humanized) immunoglobulin and human (or humanized)

Term

0.9 yearsleft in the term

Expires 29 August 2027.

  1. Priority
  2. Filed
  3. Granted
  4. Today
  5. Expires

48 members in 15 offices

This recordMember, by publication datePriority claim5 more offices are in the list below

Priority claims2

Priority claims
DocumentOfficeKindDate
84189006United States of AmericaP
2007077143United States of AmericaW

Members48

Family members, oldest first
DocumentOfficeKind
CA2661848A1CanadaA1
WO2008027515A2World Intellectual Property Organization (WIPO)A2
WO2008027986A2World Intellectual Property Organization (WIPO)A2
CL2007002536A1ChileA1
TW200817510ATaiwan Province of ChinaA
WO2008027515A3World Intellectual Property Organization (WIPO)A3
WO2008027986A3World Intellectual Property Organization (WIPO)A3
PE20081216A1PeruA1
AR062614A1ArgentinaA1
US2009053210A1United States of AmericaA1
EP2057245A2European Patent Office (EPO)A2
EP2064325A2European Patent Office (EPO)A2
CN101506235AChinaA
CN101522849AChinaA
JP2010502188AJapanA
US2010301259A1United States of AmericaA1
US2011093963A1United States of AmericaA1
SG174053A1SingaporeA1
EP2064325B1European Patent Office (EPO)B1
AT536374TThis recordAustriaT
EP2410032A2European Patent Office (EPO)A2
ES2378407T3SpainT3
PL2064325T3PolandT3
CN101506235BChinaB
CN102719444AChinaA
JP5087625B2JapanB2
US8529786B2United States of AmericaB2
CN101522849BChinaB
EP2410032A3European Patent Office (EPO)A3
CN103865492AChinaA
CA2661848CCanadaC
HK1199012A1Hong Kong, ChinaA1
EP2057245B1European Patent Office (EPO)B1
US9476027B2United States of AmericaB2
CN102719444BChinaB
CN103865492BChinaB
ES2608856T3SpainT3
US2017218336A1United States of AmericaA1
EP2410032B1European Patent Office (EPO)B1
US2019017021A1United States of AmericaA1
ES2705488T3SpainT3
EP3470491A1European Patent Office (EPO)A1
US10370641B2United States of AmericaB2
EP2410032B8European Patent Office (EPO)B8
ES2705488T8SpainT8
EP2057245B2European Patent Office (EPO)B2
ES2608856T5SpainT5
US11230697B2United States of AmericaB2